Welcome to Markets Desk, your midday read on what's moving the needle.
Citigroup is pushing deeper into digital finance, announcing an expansion of its Citi Token Services into Japan and the United Arab Emirates. The move signals growing institutional appetite for blockchain-based payments infrastructure in two of the world's most strategically important financial corridors, and underscores Citi's ambition to lead in tokenized banking at scale.
Shifting to medtech, SI-BONE received FDA five-ten-k clearance for its iFuse Granite Onyx System, extending its compromised bone platform beyond the pelvis and into spinal fusion. For a company that has built its franchise around sacropelvic procedures, this clearance opens a meaningfully larger addressable market and gives the commercial team a new growth lever heading into the back half of the year.
And on the regulatory front, Egetis Therapeutics secured full FDA approval for EMCITATE, a treatment for MCT eight deficiency, a rare genetic disorder that disrupts thyroid hormone transport in the brain. Approval covers both adults and pediatric patients, and for a small-cap biotech, this kind of orphan disease green light can be genuinely transformative for the revenue outlook.
That's the tape. Markets Desk, signing off the floor.
